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Functional Correction of Type VII Collagen
Expression in Dystrophic Epidermolysis Bullosa
Eva M. Murauer1, Yannick Gache2,3,5, Iris K. Gratz1,6, Alfred Klausegger1, Wolfgang Muss4, Christina
Gruber1, Guerrino Meneguzzi2,3, Helmut Hintner1 and Johann W. Bauer1
Functional defects in type VII collagen, caused by premature termination codons on both alleles of the COL7A1
gene, are responsible for the severe autosomal recessive types of the skin blistering disease, recessive
dystrophic epidermolysis bullosa (RDEB). The full-length COL7A1 complementary DNA (cDNA) is about 9 kb,
a size that is hardly accommodated by therapeutically used retroviral vectors. Although there have
been successful attempts to produce functional type VII collagen protein in model systems of RDEB, the risk
of genetic rearrangements of the large repetitive cDNA sequence may hamper the clinical application of
full-length COL7A1 cDNA in the human system. Therefore, we used trans-splicing to reduce the size of the
COL7A1 transcript. Retroviral transduction of RDEB keratinocytes with a 30 pre-trans-splicing molecule resulted
in correction of full-length type VII collagen expression. Unlike parental RDEB keratinocytes, transduced cells
displayed normal morphology and reduced invasive capacity. Moreover, transduced cells showed normal
localization of type VII collagen at the basement membrane zone in skin equivalents, where it assembled into
anchoring fibril-like structures. Thus, using trans-splicing we achieved correction of an RDEB phenotype
in vitro, which marks an important step toward its application in gene therapy in vivo.
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INTRODUCTION
Dystrophic epidermolysis bullosa (DEB) is a clinically severe
variant of a group of inherited autosomal dominant or
recessive (RDEB) mechanobullous diseases caused by muta-
tions in the COL7A1 gene (Pulkkinen and Uitto, 1999; Uitto
and Pulkkinen, 2001). The COL7A1 mRNA of 9.2 kb contains
118 exons and codes for the 290 kDa type VII collagen
(Christiano et al., 1994a). Type VII collagen is secreted into the
extracellular space by both dermal fibroblasts and epidermal
keratinocytes, where it self-assembles into highly organized
anchoring fibrils (AFs) that extend from the lamina densa of the
epidermal basement membrane into the underlying dermal
connective tissue and take part in securing the epidermal–
dermal adhesion (Morris et al., 1986; Burgeson, 1993;
Christiano et al., 1994b; Bruckner-Tuderman et al., 1995).
Over 400 distinct mutations spanning the entire COL7A1
gene have been identified in DEB (Dang and Murrell, 2008).
The compilation of mutation data has determined that severe
generalized RDEB phenotypes are due to premature termina-
tion codons. The molecular aberrations affect synthesis,
secretion, or molecular assembly of type VII collagen into
AFs within the dermal–epidermal junction (DEJ), leading to
separation of dermis and epidermis (Fine et al., 2008).
Patients with the most severe types of RDEB are prone to
invasive SSC, and have lifelong severe disease with con-
siderable morbidity and mortality (Mallipeddi, 2002).
Retroviral vectors are the most used vehicles in human
gene therapy trials because of their high transduction
efficiency of eukaryotic cells ex vivo and sustained expres-
sion of the transgene after transplantation in vivo (Morgan
and Anderson, 1993; Khavari et al., 2002). Therefore, most
gene therapy efforts for DEB are focused on an ex vivo
transfer of the wild-type COL7A1 complementary DNA
(cDNA) into affected keratinocytes or fibroblasts to correct
the RDEB phenotype. For example, integration of COL7A1
cDNA (8.9 kb) into human type VII collagen-null RDEB
keratinocytes and/or fibroblasts has been achieved using
PhiC31 bacteriophage integrase (Ortiz-Urda et al., 2002), a
lentiviral vector (Chen et al., 2002), as well as a retroviral
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vector (Gache et al., 2004). These studies resulted in
reversion of many RDEB symptoms after gene transfer.
However, titer and the large size of COL7A1 cDNA are
persistent problems that hamper the clinical development of
this type of vector-based gene therapy.
To overcome this problem, COL7A1 ‘‘minigenes’’ that
maintain proper biochemical functions in vitro have been
developed, and could potentially fit into retrovirus-based
gene transfer vectors (Chen et al., 2000). However, the
efficiency of proteins of reduced size in correcting a collagen
deficiency has yet to be demonstrated. An alternative strategy
includes the use of trans-splicing technology for gene
correction. Trans-splicing is a gene repair mechanism, using
the cell’s spliceosome to recombine an endogenous target
pre-mRNA and an exogenously delivered RNA mole-
cule called pre-trans-splicing molecule (PTM). A part of the
endogenously expressed target pre-mRNA is replaced by the
wild-type coding sequence from the PTM by trans-splicing
into the 30 or 50 sequence of the target to generate a new
reprogrammed mRNA (Puttaraju et al., 1999; Wally et al.,
2008). Functional RNA repair through trans-splicing has been
reported in a variety of in vitro, ex vivo, and in vivo studies
(Mansfield et al., 2000; Chao et al., 2003; Tahara et al.,
2004). The feasibility of trans-splicing to be used for correction
of a monogenic skin disease has been established in the
COL17A1 gene in an immortalized patient cell line (Dallinger
et al., 2003). Recently, we showed that 50 trans-splicing repair
of the PLEC1 gene in patient fibroblasts increased the level of
functional plectin protein by 58% (Wally et al., 2008). These
studies have laid the ground for further studies in the most
severe forms of epidermolysis bullosa (EB). Therefore, we
transduced primary human RDEB keratinocytes with a 30 PTM
to explore the correction of type VII collagen expression by
30 trans-splicing. We demonstrate here that 30 trans-splicing is
capable of fully reverting the RDEB phenotype in cell culture,
which set the basis for its application in an ex vivo gene therapy
approach in RDEB patients.
RESULTS
Retroviral transduction of human RDEB keratinocytes
with a 30 PTM vector
To evaluate the phenotypic reversion of RDEB keratinocytes
by 30 trans-splicing, we used primary keratinocytes derived
from an RDEB patient carrying two premature termina-
tion codons in COL7A1 exons 14 and 106 causing type VII
collagen deficiency. A plasmid was designed to express
PTM-S6 to repair the 30 part of the endogenous COL7A1
transcript encompassing the mutation located in exon 106
(Figure 1a). PTM-S6 contains a 224-bp binding domain
(BD) complementary to the last 188 nucleotides of the
COL7A1 intron 64 pre-mRNA and all 36 nucleotides of exon
65, typical 30 trans-splicing elements (a 31-bp spacer, a yeast
branch point, a polypyrimidine tract, and a 30 splice acceptor
site), and the 3.3-kb wild-type COL7A1 coding sequence
extending from exons 65 to 118. The BD was designed to
exclude high sequence homology with other genes, which
was verified by mapping the 224-bp BD sequence against the
human genome using the NCBI BLASTn (somewhat similar
sequences). For transduction of the RDEB keratinocytes,
PTM-S6 was inserted into the retroviral vector pLZRS-IRES-
Zeo (Michiels et al., 2000) to generate the pLZRS-PTM-S6
vector (Figure 1b). After transduction and antibiotic selection,
the RDEB cells were processed to evaluate the genetic
correction and phenotypic reversion through trans-splicing.
Long-term serial propagation of keratinocytes in culture is
sustained by the presence of epidermal cells characterized by
high differentiation and clonogenic potential (Barrandon and
Green, 1987). To achieve long-term propagation of the
transduced primary RDEB keratinocytes for further analysis,
we isolated independent colonies with a large and smooth
perimeter of cell pools, and one colony (clone no. 1) that
did not undergo senescence during serial cultivation
was selected for all subsequent experiments to analyze the
functional correction of type VII collagen expression.
The selected clone no. 1 was assessed for clonogenic
capacity by colony-forming assays at passages 8 and 20
(17 and 40 cell doublings). Clonal analysis indicated
relatively constant colony-forming efficiency values at both
passages (26–36%) (Figure 1c), suggesting that our cell
cultures contain permanently transduced clonogenic cells.
PCR analysis of genomic DNA extracted from the pool of
transduced cells and from the selected clone no. 1 using
primers specific for the pLZRS-PTM-S6 vector showed the
expected 3.6-kb amplification fragment (Figure 1d), indicat-
ing that the PTM-S6 molecule was stably integrated into the
genome of infected cells. The average proviral copy number
per cell evaluated by linear amplification-mediated (LAM)-
PCR analysis of genomic DNA extracted from transduced
cells and from the selected clone no. 1 after multiple passages
(at least 40 population doublings) indicated integration of one
single copy of pLZRS-PTM-S6 (Figure 1e).
Correction of type VII collagen expression in retrovirally
transduced RDEB keratinocytes
Immunostaining of cultured cells using an anti-type VII
collagen polyclonal antibody (pAb) was carried out to
evaluate protein expression in PTM-S6-transduced RDEB
keratinocytes (Figure 2a). Cytoplasmic staining of type VII
collagen was observed in 100% of the transduced keratino-
cytes after zeocin selection and in the RDEB-PTM-S6 clone
no. 1, suggesting that type VII collagen-null RDEB keratino-
cytes were provided with the ability to express type VII
collagen after trans-splicing repair. Immunostaining of RDEB-
PTM-S6 clone no. 1 cells after B40 doublings also showed
immunoreactivity to type VII collagen, which confirms the
sustained expression of PTM-S6 (Figure 2a). No immunor-
eactivity was detected with parental RDEB keratinocytes.
To evaluate the expression of the trans-spliced collagen VII
at the DEJ, skin equivalents (SEs) were obtained from wild-
type, RDEB, or transduced keratinocytes seeded on a dermal
equivalent composed of a fibrin matrix containing human
type VII collagen-null RDEB fibroblasts. Immunostaining with
pAb directed against type VII collagen showed that SEs
composed of PTM-S6-transduced RDEB keratinocytes clone
no. 1 at passage 6 (B13 doublings) expressed type VII
collagen at the basement membrane zone, whereas parental
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RDEB cells generated SEs that entirely lacked type VII
collagen expression (Figure 2b). The intensity of the
fluorescence signal was comparable to that observed in SEs
obtained from wild-type keratinocytes. Localization was
restricted to the basement membrane, with no expression in
suprabasal cells. SEs obtained from the transduced cell clone
after B40 doublings still showed expression of type VII
collagen at the DEJ (Figure 2b).
Transmission electron microscopy was performed on SEs to
determine whether trans-splicing repair leads to restoration of
AF formation at the basement membrane zone. Ultrastructural
examination of the DEJ showed that the type VII collagen
expressed and secreted by the corrected keratinocytes
assembled into AF-like structures. Moreover, mature hemides-
mosomes and a defined lamina densa indicate formation of a
mature basement membrane. In contrast, SEs obtained from
RDEB keratinocytes displayed a loose lamina densa, sparse
hemidesmosomes, and entirely lacked AF (Figure 2c).
Reversion of the RDEB morphology and reduction
of the invasive potential of RDEB keratinocyes
It has been reported that cultured RDEB keratinocytes
display a different morphology from normal keratinocytes
(Chen et al., 2002). Moreover, compared with normal human
keratinocytes, RDEB keratinocytes lacking type VII collagen
show increased invasion properties ex vivo (Gache et al.,
2004), which is consistent with the proneness to develop
invasive cancers in patients with RDEB (Mallipeddi, 2002;
Martins et al., 2009). To determine whether synthesis of type
VII collagen by transduced RDEB keratinocytes exerts any
functional effects on RDEB cells, we first analyzed the
morphology of cells in culture before and after transduction.
As shown in Figure 3a, RDEB keratinocytes in culture display
an unusual size and elongated shapes with multiple cellular
protrusions. These features are in contrast to the typical
polygonal morphology observed in normal human keratino-
cytes. Compared with parental RDEB keratinocytes, PTM-S6-
transduced RDEB keratinocytes demonstrated a shape and
size that were similar to that of normal keratinocytes,
suggesting that correction of type VII collagen expression in
RDEB keratinocytes caused RDEB cells to convert to normal
morphology.
To further explore the functional consequences of correc-
tion of type VII collagen expression by trans-splicing,
cell invasion was assessed using in vitro invasion assays.
We demonstrated that the de novo expression of type VII
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Figure 1. Retroviral transduction of recessive dystrophic epidermolysis bullosa (RDEB) keratinocytes with a 30 pre-trans-splicing molecule (PTM). (a) Trans-splicing
between the 50-splice site (50ss) of the endogenous COL7A1 pre-mRNA and the 30-splice site (30ss) of the exogenously transduced PTM-S6 results in a reprogrammed
COL7A1 transcript, consisting of endogenous exons 1–64 (white) and delivered exons 65–118 (gray). (b) pLZRS-PTM-S6 vector comprising the Moloney mouse
sarcoma virus long terminal repeat (LTR), the 3.6-kb PTM-S6, an internal ribosome entry (IRES), and a Zeocine-resistance gene. (c) Clonal analysis of keratinocyte
cultures of clone no. 1 at passages 8 and 20 shows comparable clonogenic potential. (d) PCR analysis of PTM-S6 integration in the genome of RDEB- and PTM-S6-
transduced keratinocytes. pLZRS, amplified product from plasmid pLZRS-PTM-S6. (e) Linear amplification-mediated-PCR analysis of genomic DNA of transduced
RDEB cells showed one retroviral integration event. BP, branch point; CFE, colony-forming efficiency; PPT, polypyrimidine tract; wt, wild-type.
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collagen significantly impaired the capacity of transduced
RDEB keratinocytes to invade Matrigel-coated Transwell
chambers (Figure 3b). These results attest the biological
activity of the trans-spliced type VII collagen expressed by
corrected RDEB keratinocytes.
Expression and secretion of full-length type VII collagen
by corrected RDEB cells
Immunoblot analysis was performed on spent medium
from RDEB cell cultures using anti-type VII collagen pAb
(Figure 3c). The type VII collagen band was completely
absent in the parental RDEB cell culture medium. Analysis of
normal human keratinocyte-conditioned medium showed
a band with a molecular mass of 290 kDa, corresponding to
the size of full-length type VII collagen. This band was also
detected in the transduced RDEB cell culture medium. No
other band migrating at a different size was detectable.
Expression as measured by western blot analysis was
sustained for over 40 doublings in vitro. These results
indicate that trans-splicing of PTM-S6 in transduced RDEB
keratinocytes generates long-term expression and secretion of
the full-length type VII collagen protein in vitro.
Increased expression levels of COL7A1 mRNA
after trans-splicing
To assess the level of COL7A1 transcripts, semiquantitative
real-time PCR analysis was performed. RDEB patient
keratinocytes that did not express type VII collagen showed
much less COL7A1 mRNA relative to GAPDH than did
normal keratinocytes (Figure 3d). Corrected keratinocytes
have a twofold increase compared with RDEB patient
keratinocytes, indicating efficient trans-splicing. Western
blot analysis showed that this level is sufficient to
express full-length type VII collagen protein in almost equal
amounts than expressed by normal keratinocytes in vitro
(Figure 3c).
To be able to detect trans-spliced COL7A1 mRNA, five
silent mutations were included on the PTM-S6 COL7A1
coding sequence. Reverse transcriptase-PCR (RT-PCR) analy-
sis of RNA extracted from transduced cells using a forward
primer specific for the endogenous COL7A1 portion and a
reverse primer specific for the portion of PTM-S6 carrying
silent mutations showed the expected 216-bp fragment,
attesting to the presence of trans-spliced COL7A1 mRNA.
This band was completely absent in the RT-PCR analysis of
untreated RDEB cells (Figure 3e). Subsequent sequence
analysis of the amplified fragment confirmed correct trans-
splicing (not shown).
DISCUSSION
In this study, we showed that 30 trans-splicing is capable of
repairing functional aberrations of type VII collagen in RDEB
keratinocytes. Using a designed RNA trans-splicing construct,
we restored the synthesis of type VII collagen molecules in
keratinocytes isolated from an RDEB patient. The synthesis of
type VII collagen reverted the morphology and invasion
capacity of RDEB cells, is restricted to the DEJ, and promotes
the formation of AFs in vitro.
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Figure 2. Reexpression of type VII collagen in 30pre-trans-splicing molecule (PTM)-S6-transduced recessive dystrophic epidermolysis bullosa (RDEB)
keratinocytes and at the dermal–epidermal junction of organotypic skin equivalents (SEs). (a) Immunofluorescence analysis of cultured keratinocytes showed
no collagen VII staining in parental RDEB keratinocytes (RDEB), and positive staining in normal keratinocytes (NHK), PTM-S6-transduced cell pool (RDEB-PTM-
S6), and clone no. 1 (RDEB-PTM-S6, clone no. 1). Bar¼ 20mm. (b) Immunostaining for collagen VII is negative in SEs with RDEB keratinocytes (RDEB), and
positive in SE with transduced RDEB keratinocytes at passages 4 and 20 (RDEB-PTM-S6, clone no. 1, p4/p20), comparable to the staining in normal SEs (NHK).
Cell nuclei were counterstained with 4’,6-diamidino-2-phenylindole dye. Bar¼ 100mm. (c) Electron microscopy analysis shows no anchoring fibril (AF) in SEs
of RDEB keratinocytes (RDEB), whereas rudimentary AFs are observed underneath the lamina densa in SEs of PTM-S6-transduced cells (RDEB-PTM-S6,
clone no. 1). Bar¼ 100nm. BM, basement membrane; HD, hemidesmosomes.
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In the last decade, significant research has been conducted
investigating strategies to correct the RDEB phenotype caused
by COL7A1 mutations. Studies using an antisense oligoribo-
nucleotide (Goto et al., 2006), a P1-based artificial chromo-
some comprising a COL7A1 gene (Mecklenbeck et al., 2002),
transduction of a COL7A1 minigene construct (Chen et al.,
2000), or the full-length COL7A1 cDNA with viral
vectors (Chen et al., 2002; Ortiz-Urda et al., 2002; Baldeschi
et al., 2003; Gache et al., 2004) have shown the possible
restoration of type VII collagen expression in RDEB skin
cells either in vitro or in grafted mice models. However,
limitations of these therapy strategies include (1) the short-
term correction of the phenotype (Goto et al., 2006), (2) the
production of a truncated type VII collagen that may induce
dominant-negative interference (Chen et al., 2000), (3) the
unstable accommodation of the large type VII collagen
transgene (9.2 kb) in viral vectors, and (4) the ectopic
expression of the recombinant type VII collagen in all layers
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Figure 3. Functional correction of type VII collagen expression by trans-splicing. (a) Light microscopy of cell cultures. Recessive dystrophic epidermolysis
bullosa (RDEB) parental keratinocytes; arrow, unusual shape; arrowhead, unusual size; normal human keratinocytes (NHK); (RDEB-30 pre-trans-splicing
molecule (PTM)-S6) PTM-S6-transduced RDEB keratinocytes. Bar¼ 10mm. (b) PTM-S6-transduced RDEB keratinocytes display impaired invasive potential
compared with parental RDEB keratinocytes. Shown are mean±SD of triplicate values. (c) Immunoblot analysis indicates the absence of collagen VII in RDEB
keratinocytes (1), whereas NHK (2) and PTM-S6-transduced RDEB keratinocytes (3) show secretion of full-length collagen VII. (d) Semiquantitative reverse
transcription-PCR analysis of COL7A1 mRNA expression shows low levels in RDEB keratinocytes compared with NHK, and a twofold increase
in PTM-S6-transduced RDEB cells. (e) Reverse transcriptase-PCR analysis of COL7A1 mRNA using trans-specific primers shows a band specific for trans-splicing
in PTM-S6-transduced RDEB keratinocytes (1), undetectable in non-transduced RDEB keratinocytes (2).
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of the reconstituted transgenic epidermis (Baldeschi et al.,
2003; Gache et al., 2004). In this study, we have shown that
trans-splicing technology allows an endogenously regulated
synthesis of type VII collagen, and has the potential to
circumvent the problem of truncated expression of the
recombinant protein.
To correct type VII collagen defect in RDEB patient
keratinocytes by 30 trans-splicing, intron 64 was specifically
targeted, allowing the reduction of 9.2-kb COL7A1 cDNA to
a 3.3-kb transgene. The reduction of the size of the COL7A1
cDNA transgene may facilitate stable retroviral packaging
and transduction of cells, and allows the correction of one-
third of all COL7A1 mutations described in various forms of
DEB (Dang and Murrell, 2008) by a single 30 PTM construct.
Immunofluorescence analysis of PTM-S6-transduced RDEB
keratinocytes isolated from a patient bearing heterozygous
nonsense mutations in exons 13 and 106 showed positive
staining to type VII collagen in 100% of treated cells,
indicating that the delivered PTM-S6 confers successful trans-
splicing of COL7A1 transcripts in vitro. Thus, our designed
PTM can correct the phenotype of RDEB cells bearing
mutations downstream of exon 65. Furthermore, we have
shown in SEs obtained from transduced keratinocytes that
expression of the recombinant type VII collagen is restricted
to the basement membrane zone, consistent with the idea
that the recombinant type VII collagen is tightly regulated in
the PTM-S6-corrected keratinocytes in stratified epithelia.
This is different from previous studies in which RDEB
keratinocytes, transduced with full-length COL7A1 cDNA,
showed ectopic expression of the recombinant protein in the
suprabasal layers of the epidermis in SEs (Baldeschi et al.,
2003; Gache et al., 2004).
Besides endogenous regulation, the level of expression of
the recombinant protein at the DEJ is crucial for full reversion
of the RDEB phenotype in vivo. Individuals who are
heterozygous carriers of a nonsense mutation in the COL7A1
gene do not have skin blistering, suggesting that the amount
of type VII collagen necessary to prevent blistering lies
somewhere between 0 and 50% (Tidman and Eady, 1985).
Transgenic mice expressing type VII collagen at 10% of
normal levels in the skin exhibit a milder phenotype and
survive to adulthood (Fritsch et al., 2008), whereas type VII
collagen knockout mice die early after birth (Heinonen et al.,
1999). Therefore, a relatively low level expression of type VII
collagen protein may be sufficient for restoration of the
dermal–epidermal adhesion over long periods of time.
Western blot analysis showed that PTM-S6-corrected RDEB
keratinocytes synthesize and secrete full-length protein in an
amount comparable to that of normal human keratinocytes.
Using in vitro invasion assays, we also demonstrated that
restoration of type VII collagen expression by trans-splicing
significantly reduced the invasive migration potential of
RDEB keratinocytes. These data indicate that trans-splicing
through our delivered PTM-S6 leads to synthesis of enough
type VII collagen protein to revert the invasive phenotype of
RDEB cells in vitro.
Gene therapies using retroviral vectors may raise serious
safety concerns because of the genotoxic risk associated with
the insertion of viral long terminal repeat elements into the
genome (Baum et al., 2003; Hacein-Bey-Abina et al., 2003;
Fischer and Cavazzana-Calvo, 2005). One approach to make
gene therapy safer in inherited skin diseases might be the
safety preassessment of isolated genetically modified stem
cells and their progeny before transplantation into RDEB
patients (Del Rio et al., 2004; Porteus et al., 2006). Larcher
et al. (2007) have recently demonstrated the long-term in vivo
regenerative capacity of single-targeted human epidermal
holoclones, using optimized organotypic culture and grafting
methods onto nude mice. In this context, we have evaluated
the long-term expression of the recombinant protein pro-
duced by the trans-splicing mechanism in transduced
clonogenic cells. We showed that one clone, which under-
went at least 40 population doublings, is able to synthesize
full-length type VII collagen in culture and produce AFs in
reconstructed SEs. The persistent expression of type VII
collagen in the PTM-S6 clone indicates that, after integration
site analysis, it may potentially be used for long-term in vivo
correction of the RDEB phenotype. As an in vitro system
cannot explore issues of long-term expression of corrective
type VII collagen in vivo, studies are under way to test the
regenerative performance of trans-spliced gene-corrected
clones on immunodeficient mice engrafted with human skin
(Del Rio et al., 2002; Larcher et al., 2007). Currently, EB
mouse models to analyze 30 trans-splicing are not available
because of either perinatal lethality of type VII collagen
knockout (Heinonen et al., 1999) or unsuitable location of
mutations in mice with conditional inactivation of type VII
collagen (Fritsch et al., 2008). The recently published
surviving transgenic RDEB mouse model expressing human
COL7A1 cDNA with a c.7528delG mutation (Ito et al., 2009)
is also not suitable for our approach, as trans-splicing repair
reprograms gene expression at the pre-mRNA level and
requires the presence of intronic sequences.
This is the first demonstration of an in vitro gene
therapeutic approach for the COL7A1 gene that exploits the
endogenous RNA regulatory mechanisms of type VII collagen
expression in human keratinocytes. Following the successful
junctional EB gene therapy clinical assay reported by Mavilio
et al. (2006), our long-term goal is to use the 30 trans-splicing
model for an ex vivo gene therapy approach for DEB patients.
Our results may pave the way for the application of 30 trans-
splicing in gene therapy in vivo that covers mutations over
3300 nucleotides in the COL7A1 gene. As this technology
repairs mutations in genetic diseases, regardless of the mode
of inheritance, it may provide a new tool for treatment of both
recessive and dominant dystrophic EB.
MATERIALS AND METHODS
Cell cultures
Primary human keratinocytes and fibroblasts were obtained
from skin biopsy samples from type VII collagen-null RDEB
patients and healthy controls. The primary keratinocytes used
for retroviral transduction were derived from an RDEB patient
heterozygous for mutations R578X and 7786delG in exons
13 and 104 of the COL7A1 gene, respectively. Keratinocytes
were cultured on feeder layers of lethally irradiated mouse
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J2-3T3 fibroblasts in DMEM:Ham’s F-12 (3:1) (HyClone/
Perbio Science, Bezons, France) (Rheinwald and Green,
1975), or without feeder layers in EpiLife medium (Cascade
Biologics, Portland, OR). 3T3-J2 fibroblasts and dermal
fibroblasts were grown in DMEM, supplemented with
4-mM glutamine and 10% fetal calf serum (HyClone). The
Phoenix amphotropic packaging cell line was grown in
DMEM, 2-mM glutamine, 2-mM sodium pyruvate, and 10%
inactivated FCSII (HyClone) (Nolan and Shatzman, 1998).
Construction of PTM-S6 in retroviral expression vector
PTM-S6 consists of a 224-bp BD, complementary to 188
nucleotides of the 30 end of intron 64 and 36 nucleotides of
the 50 end of COL7A1 exon 65, a 31-bp spacer, which
separates the 30 splice region from the target BD, a branch
point, and a polypyrimidine tract, followed by a 30 splice
acceptor site (CAG) and the 30 wild-type coding sequence
(5648–8951-bp) of human COL7A1. The 76-bp sequence
spanning the spacer, branch point, and polypyrimidine tract
was obtained by PCR amplification of PTM5 (Dallinger et al.,
2003) with PfuTurbo DNA-Polymerase (Stratagene, La Jolla,
CA) and cloned into pcDNA3.1D/V5-His-TOPO (Invitrogen,
Carlsbad, CA) (Primers: F:50-caccgaattcatcgatgttaacgagaacatt
attatagcgttg-30; R:50-gctagcaaaaaaaagaagaggtaccag-30). The
224-bp BD was amplified from human genomic DNA using
primers F:50-gttaaccttcctcccgtcttctccag-30 and R:50-gttaaccct
atgcaggcacaccccta-30. The PCR amplification product was
cloned into the HpaI restriction site to yield the pcDNA3.1-S6
vector. The 3.3-kb fragment of wild-type human COL7A1
spanning exons 65–118 (nucleotide 5648–8951; genbank
accession number L02870) was obtained by a one-step
RT-PCR amplification (SuperScript One-Step RT-PCR for
Long Templates with Platinum Taq; Invitrogen) of total RNA
purified from wild-type human keratinocytes using primers
F:50-ctaggctagcctgcagggagaacctggggaccc-30 and R:50-ctagg
atatcgaattctcagtcctgggcagtacctg-30. The amplified product
was digested with NheI and EcoRV and cloned into the
pcDNA3.1-S6 plasmid to generate plasmid termed
pcDNA3.1-PTM-S6. The correct sequence was confirmed
by sequencing with an ABI PRISM dye terminator cycle
sequencing kit (Applied Biosystems, Foster City, CA). The
PTM-S6 cDNA was then subcloned into the moloney-derived
pLZRS-IRES-Zeo retroviral vector (gift from GP Nolan,
Stanford University, Stanford, CA) (Michiels et al., 2000)
between EcoRI and SNaBI restriction sites to yield the pLZRS-
PTM-S6 vector. The recombinant plasmid pLZRS-PTM-S6-
IRES-Zeo was amplified in the Escherichia coli XL10-Gold
strain (Stratagene, Amsterdam, The Netherland), purified with
a QIAquick kit (Qiagen, Courtaboeuf, France), and subjected
to sequencing.
Retroviral transduction of keratinocytes
The recombinant plasmid pLZRS-PTM-S6 was transfected
into Amphotropic Phoenix packaging cells (Phoenix-ampho)
(Nolan and Shatzman, 1998). pLZRS-PTM-S6 recombinant
viruses were harvested from cell culture medium 48hours
after transfection and RDEB keratinocytes (2 105 cells cm2)
were transduced with the viral suspension in the presence of
5 mgml1 of polybrene at 321C in humid atmosphere, 5%
CO2. Fresh culture medium was added 2 hours later and cells
were incubated overnight at 321C. Transduced cells were
then fed with keratinocyte growth medium and selected in
the presence of 200 mgml1 of Zeocin (Invitrogen) for 7 days.
PCR analysis of genomic DNA
For detection of transgenic PTM in transduced keratinocytes,
genomic DNA was isolated from confluent cultures using
the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany)
and analyzed by PCR amplification. A 3.6-kb fragment was
amplified with vector-specific primers using Expand Long
Range dNTPack (Roche, Mannheim, Germany). The forward
primer (50-agacggcatcgcagcttgg-30) binds to the pLZRS
vector sequence upstream of the BD, and the reverse primer
(50-tctagagaattctcagtcctgggcagtacctg-30) is complementary to
the last COL7A1 exon on the pLZRS-PTM vector. Another
PCR was performed to verify the chromosomal integration of
the pLZRS-PTM and to exclude the possibility of amplifica-
tion of an episomal replicated pLZRS-PTM vector using
primers F:50-atgtctgagaggggccag-30 and R:50-ctcctgctcctgttc
cacc-30, which bind outside the long terminal repeat regions
of the retroviral LZRS vector.
LAM-PCR analysis
Proviral copy numbers were determined on 50 ng of genomic
DNA extracted from PTM-S6-corrected RDEB keratinocytes.
The unknown genomic DNA flanking the 50 long terminal
repeat was identified using LAM-PCR, as described (Schmidt
et al., 2003; Schwarzwaelder et al., 2007). In brief, two
50 biotinylated long terminal repeat-specific vector primers,
50-tgcttaccacagatatcctg-30 and 50-atcctgtttggcccatattc-30, were
used for the initial linear PCR. The single-stranded genomic-
proviral junction product was purified on streptavidin-coated
magnetic beads, made double stranded in a randomly primed
Klenow reaction, and digested with Tsp509I. The extended
end was ligated to a double-stranded synthetic anchor primer
(F:50-gacccgggagatctgaattcagtggcacag-30 and R:50-aattctgtgcc
actgaattcagatctcccgggtc-30). The genomic-proviral junction
region was then amplified by two rounds of nested PCR using
primers F1:50-gacccgggagatctgaattc-30 and F2:5-gatctgaattca
gtggcacag-30 and R1:biotinylated 50-gcccttgatctgaacttctc-30
and R2:50-ttccatgccttgcaaaatggc-30. Products were analyzed
on a 2% MetaPhor Agarose gel (Cambrex, Rockland, ME).
LAM-PCR amplicons were isolated and sequenced. The
sequence of the LAM-PCR product was mapped against the
human genome using NCBI BLASTn (http://blast.ncbi.nlm.
nih.gov/Blast). Its relation to annotated genome features was
studied using the Ensembl database (http://www.ensembl.org).
Isolation of clonogenic cells and colony-forming efficiency
assay
Transduced RDEB keratinocytes at passage 2 after Zeocin
selection were used for the isolation of single clonal cells.
Transduced RDEB keratinocytes (103) were seeded onto
feeder layers in 100-mm Petri dishes. After 14 days in cul-
ture, cell colonies with regular perimeters and large
diameters were isolated with cloning rings, trypsinized, and
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individually expanded for further analysis. Colony-forming
efficiency of the cultured keratinocytes was determined
by plating the cells at densities of 5 and 10 cells cm2 on a
feeder of lethally irradiated 3T3-J2 fibroblasts. After 14 days,
colonies were stained with rhodamine blue. Values of
colony-forming efficiency were calculated as the percentage
of inoculated cells that gives rise to colonies.
Population doublings
To calculate the population doubling level per passage, cells
were removed by trypsinization at confluence and counted,
and the number of doublings was calculated as log(number of
cells at time of subculture/number of cells plated)/log2.
Invasion assays
For in vitro invasion assays, BD BioCoat Control or Matrigel
Invasion chambers (BD Biosciences Discovery Labware,
Bedford, MA) were rehydrated for 2 hours at 371C by adding
500ml of DMEM to the interior of the inserts and to the
bottom of wells. Thereafter, 5 104 cells in 500ml of serum-
free DMEM were seeded into the upper chamber. The lower
chamber was filled with DMEM containing 10% fetal calf
serum and 25 ngml1 of EGF. After 24 hours at 371C, non-
invading cells were removed from the upper surface of the
membrane using a cotton swab, and cells attached to the
lower surface of the membrane were fixed with methanol,
stained with Toluidine Blue, and counted in four randomly
selected microscopic fields (200 magnification) of tripli-
cate membranes. Invasion data were expressed as the
percentage invasion through the Matrigel membrane relative
to the migration through the control membrane. Each
experiment was conducted in duplicate.
Organotypic cultures
SEs were generated using human fibrin as a scaffold (Meana
et al., 1998). Type VII collagen-deficient fibroblasts were
embedded in the fibrin gel-matrix in six-well plates and
immersed in DMEM for 24 hours at 371C and 5% CO2.
Primary keratinocytes (2105 cells per well) were seeded on
the matrix, grown to confluence in DMEM:F-12 keratinocyte
medium containing 50 mgml1 of ascorbic acid, and raised
at the air–liquid interface for 28 days to favor stratification
and differentiation into an epithelium. SEs were manually
detached from the plates and processed for electron
microscopy analysis or embedded in optimal cutting temper-
ature compound (Sakura, The Netherlands), frozen in liquid
nitrogen, and cut into 6-mm sections for immunofluorescence
staining.
Immunofluorescence staining
For immunofluorescence analysis of monolayer keratinocyte
cultures, cells (5103) were seeded on glass coverslips and
fed for 48 hours with medium supplemented with 50 mgml1
of ascorbic acid. Cells were permeabilized and fixed in cold
methanol, and incubated for 1 hour with a pAb directed
against type VII collagen (Calbiochem, San Diego, CA)
diluted at 1:200 in 2% BSA. The secondary Ab used was
Alexa-Fluor-488 goat antirabbit IgG (Invitrogen). Sections of
frozen SEs were fixed in acetone and immunofluorescence
staining of type VII collagen was performed using the same
protocol as described above. Cell cultures and skin sections
were analyzed using an epifluorescence Zeiss Axiophot
microscope (Carl Zeiss, Oberkochen, Germany).
Transmission electron microscopy
Small slices of SE specimens were fixed in phosphate-
buffered formaldehyde–glutaraldehyde solution, followed
by osmication, dehydration in ascending ethanol, and
processing into epoxy resin (Glycidether 100, with hardeners
dodecenyl succinic anhydride, methyl-5-norbornene-2,
3-dicarboxylic anhydride, and 2,4,6-tris(dimethylamino-
methyl)-phenol-30; Serva, Heidelberg, Germany). Ultrathin
sections (80 nm) were stained by a standardized method
using tannic acid, uranyl acetate, and lead citrate (Venable
and Coggeshall, 1965; Dingemans and van den Bergh
Weerman, 1990). Observations and micrographic documen-
tation were performed using an electron microscope at 80 kV
(Zeiss EM 109; Carl Zeiss), using a 35-mm camera and
negative film (Kodak TPF 2415 Estar base, Eastman Kodak
Company, Rochester, NY). The negatives were scanned and
digitized.
Western blot analysis
For immunoblot analysis, keratinocytes were grown to
confluence in a conditioned medium (Epilife) and then fed
for 48 hours with serum-free Epilife medium containing
50 mgml1 of ascorbic acid. Media were collected and
concentrated 15- to 20-fold (Amicon Ultra-15, Millipore,
Billeria, MA) in the presence of protease inhibitors (Complete
Mini protease inhibitor cocktail tablets, Roche, Vienna,
Austria). Equal amounts of samples were subjected to
electrophoresis on a denaturing 6% SDS-PAGE and trans-
ferred to a nitrocellulose membrane (Hybond-TM-ECLTM,
Amersham Biosciences, Buckinghamshire, UK) by electro-
blotting according to standard procedures. For type VII
collagen analysis, blots were reacted with the anti-type VII
collagen pAb (Calbiochem) diluted at 1:500 in blocking
buffer (0.5% Western Blocking Reagent, Roche, Mannheim,
Germany). A pAb to human MMP-2 (Abcam, Cambridge, UK)
was used as internal control of protein quality and loading.
Secondary antibodies were goat antirabbit IgG-HRP (Abcam,
Cambridge, UK). Bands were visualized using SuperSignal
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).
Semiquantitative real-time PCR and RT-PCR analysis
to detect COL7A1 trans-splicing
The BioRad CFX96TM system (Bio-Rad, Munich, Germany)
was used to determine levels of COL7A1 mRNA in normal
keratinocytes, as well as in parental and transduced RDEB
keratinocytes. COL7A1 primers (F:50-gtgaggactgcccctgag-30
and R:50-gactccaccttcgagaccc-30) were designed to amplify a
210-bp fragment spanning exons 17–19. PCR reactions using
25-ng cDNA template and iQ SybrGreen Supermix (Bio-Rad)
were carried out in duplicate and standard deviation was
calculated from three independent experiments. Trans-
cript levels were calculated after normalization to the
www.jidonline.org 81
EM Murauer et al.
Correction of COL7A1 Mutations by Trans-Splicing
housekeeping gene GAPDH (F:50-gccaacgtgtcagtggtgga-30
and R:50-caccaccctgttgctgtagcc-30).
To discriminate between trans- and cis-spliced COL7A1
mRNA, we incorporated five silent mutations in exons 65–66
on the PTM-S6 vector. A 216-bp trans-spliced COL7A1
mRNA fragment was obtained by one-step RT-PCR amplifi-
cation (SuperScript One-Step RT-PCR, Invitrogen) of total
RNA isolated from PTM-S6-transduced keratinocytes, using
a forward primer hybridizing with endogenous COL7A1
exons 61–62 (50-tgggccgaatggtgctgca-30) and a reverse primer
specifically binding the position of the silent mutations
of PTM-S6. (50-ctgaatctcccttttcacccttacg-30). The correct seq-
uence was confirmed by direct DNA sequence analysis.
Endogenous cis-splicing was detected using the same for-
ward primer and a wild-type-specific reverse primer
(50-ctttctctcccttcctcccg-30) to amplify a 200-bp fragment.
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